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ABSTRACT 
Liver transplantation is the only definitive treatment for transthyretin amyloidosis, with an 
excellent 5-year survival in endemic countries where the Met30 mutation is predominant. We 
report our experience of liver transplantation for transthyretin amyloidosis. We reviewed the 
clinical records of 17 transplanted patients (11 males, 6 females; age at liver transplant: 
45.7±11.7 years).  
We had a wide spectrum of non-Met30 mutations (52.9%), with a predominance of  Gln89 
(23.5%). Five-year survival after transplantation was 43.8%; at multivariate analysis, both non-
Met30 mutations (HR 17.3, 95% CI 1.03-291.7) and modified BMI (HR 0.50, 95% CI 0.29-0.87) 
showed significant and independent prognostic roles (P=0.048 and P=0.015, respectively). Five 
out of the 9 non-Met30 carriers received combined heart transplantation because of severe 
cardiomyopathy; they showed a trend towards a better prognosis vs. the 4 patients who did not 
receive combined heart transplantation (although not statistically significant; P=0.095). At 
follow-up, no significant improvement of  transthyretin amyloidosis manifestations was observed. 
The results of liver transplantation for transthyretin amyloidosis in our population are poorer  
than those reported in the literature probably because of the high prevalence of non-Met30 
mutations. 
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BACKGROUND AND AIMS 
Transthyretin (TTR) amyloidosis is an autosomal, late-onset disease, caused by the mutation of a 
single gene on chromosome 18 codifying for TTR, a tetrameric physiologic plasma protein. To 
date, more than 100 different amyloidogenic mutations have been reported (1); the substitution of 
valine by methionine at position 30 (Met30) is by far the most frequent, with well-known 
endemic foci in Portugal, Sweden and Japan. Amyloidogenic mutations destabilize the molecule, 
favouring tetramer dissociation, with the generation of unstable intermediates which are prone to 
precipitate and to self-aggregate into amyloid fibrils in tissues, impairing their structure and 
function.  
Over 95% of the mutated protein is produced by the liver, and typically affects the peripheral 
nervous system and the heart, leading to disabling sensory-motor and autonomic neuropathy, 
arrhythmias, and restrictive cardiomyopathy. In the Met30 mutation, peripheral neuropathy 
dominates the clinical picture and death occurs 7 to 10 years after the onset of symptoms. In 
many rarer mutations, clinically relevant cardiac involvement, which is generally a late 
phenomenon among Met30 carriers, appears to be the predominant feature (2, 3, 4, 5, 6 )  
Furthermore, all the TTR variants can potentially be associated with  mutated protein production 
by the choroid plexus and the vitreous (7) In this setting, we can observe, leptomeningeal, 
cerebrovascular and nerve root deposits with the risk of infarction or haemorrhage, and vitreal 
deposits with reduced vision reduction and glaucoma. Since  leptomeningeal deposits and ocular 
involvement are frequently associated, these forms are referred to as familial leptomeningeal or 
oculoleptomeningeal amyloidosis (8, 9, 10, 11, 12, 13, 14, 15, 16, 17) 
Currently, liver transplantation (LT), abolishing the supply of mutated protein, represents the 
only definitive treatment for TTR amyloidosis, with an excellent 5-year patient survival.rate. 
However, a significantly lower survival rate has been reported in patients with non-Met30 
mutations, mainly because of perioperative cardiac complications (18, 19). Moreover, 
progression of amyloidotic cardiomyopathy (20, 21, 22, 23) and progression or de novo 
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oculoleptomeningeal deposits after surgery (24) have been decribed. Vitreous deposits can  easily 
be treated, while the issue of LT for leptomeningeal variants remains to be evaluated.  
 
An interesting corollary of performing LT in patients with TTR amyloidosis is the possibility of 
using their removed liver for grafting into another patient with end-stage liver disease, a 
procedure called domino LT. The pending problem is the risk of de novo amyloidosis in the 
recipients of the amyloidotic liver; although, in the first series, none showed symptoms of the 
disease (18),  a case of systemic TTR amyloidosis has recently been reported (25).  
 
We herein report  our experience of LT for TTR amyloidosis in a single Italian transplant center. 
Some of our cases have been previously reported as single case reports. The aim of the present 
study was to analyze the entire group of transplanted patients  in order  to assess patient survival 
and the relative prognostic factors. The secondary goals were to evaluate the course of the disease 
after LT and the results of domino LT.  
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PATIENTS AND METHODS  
From May 1993 to May 2006, 17 patients underwent 18 LTs for TTR amyloidosis at our 
Institution, 5 of whom also received heart transplantation (HT). Their clinical records  at the time 
of surgery were reviewed. In order to evaluate the course of the disease after LT, the same data 
were evaluated at the time of the last follow-up; a minimum follow-up of 6 months was 
considered suitable to detect clinical modifications. 
Peripheral sensory-motor damage was classified into 4 stages: absent; mild sensory (thermo-
dolorific) deficit limited to the lower limbs; global sensory loss extending to the upper limbs with 
motor involvement in lower limbs (distal muscle atrophy and steppage gait); unable to walk 
(bedridden or wheelchairbound). This scale was chosen because it has been specifically validated 
in amyloidotic patients (26).In order to assess nutritional status , we calculated the modified body 
mass index (mBMI), according to Suhr et al. (27, 28, 29) The presence of gastrointestinal 
symptoms, bladder dysfunction, orthostatic hypotension and  erectile dysfunction in men were 
also evaluated in order to characterize  the involvement of the autonomic nervous system.  
Heart involvement was assessed by echocardiography and electrocardiography. The presence of 
amyloidotic cardiomyopathy was defined as end-diastolic thickness of the interventricular septum 
>12 mm (in the absence of any other cause of ventricular hypertrophy) plus two or more of the 
following: (a) homogeneous atrioventricular valve thickening, (b) atrial septal thickening and (c) 
sparkling appearance of the ventricular septum (30). The left ventricular mass, which was 
calculated according to the formula reported by Devereux et al.(31), was considered increased 
when >130 g/m2 in men and >110 g/m2 in women. An ‘abnormal electrocardiogram’ was 
defined according to the presence of one or more of the following features: conduction 
disturbances (right bundle branch block, left bundle branch block, left anterior hemiblock, 
atrioventricular block), low QRS voltage (QRS amplitude ≤0.5 mV in all limb leads or ≤1 mV in 
all precordial leads), ST and T wave abnormalities, and ‘pseudoinfarction’ pattern.. Patients with 
echocardiographic signs of amyloidosis underwent endomyocardial biopsy, and the amounts of 
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amyloid deposits were semiquantitatively classified as mild (<30% involvement of the tissue 
fragments), moderate (30% to 60% involvement) or severe (>60% involvement) (32).  
Five out of 17 harvested grafts from patients with TTR amyloidosis were used for sequential LT 
in 5 patients; the clinical data of the recipients of domino LT at the time of surgery and at the last 
follow-up were reviewed.  
 
The study was conducted according to the principles of the Helsinki declaration. The data were 
collected in the course of routine clinical practice. Informed consent was obtained before the 
instrumental examinations according to the protocol of the institution which performed the 
evaluations.  
Statistical analysis  
Means, standard deviations, frequencies and ranges were used as descriptive statistics for the 
data; median follow-up times were also reported. The Fisher’s exact, the Pearson and the linear-
by-linear association chi-square, and the McNemar, the Mann-Whitney and the Wilcoxon tests 
were used to analyze the data. The cumulative proportion of surviving patients over time, as well 
as the mean survival times together with their 95% confidence intervals (95% CI) were estimated 
according to the Kaplan-Meier method. The univariate and multivariate Cox’s proportional 
hazard regression model was used to identify predictors of survival and the hazard ratios (HRs) 
were reported together with their 95% CI. Two-tailed P values less than 0.05 were considered 
significant. Data were analyzed by means of the SPSS for Windows version 12.0. 
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RESULTS 
Basal characteristics 
In our population, we observed a low prevalence of patients with the Met30 mutation (8/17; 
47.1%). Among mutations other than Met30, we had a predominance of the Gln89 variant (4/17; 
23.5%); and one case each of the other non-Met30 mutations represented 29.4% (Ala49, Arg47, 
Leu68, Pro36, Thr34). 
The characteristics of the 17 transplanted patients at the time of surgery are reported in Table 1. 
Combined HT-LT was performed in 5 patients, , because of severe cardiomyopathy, which was 
symptomatic in 3 (NYHA 2-3). Four patients were carriers of Gln89 and 1 was a carrier of 
Leu68. 
Survival 
Eight out of 17 patients (47.1%) died after transplant. The overall 1-year and 5-year survival rates 
were 70.1% and 43.8%, respectively, with a mean survival of 6.4 years (95% CI 3.1-9.7 years).  
Two patients with the Met30 mutation died from causes related neither to surgery nor to TTR 
amyloidosis:a 30-year-old male in a car crash and a 38-year-old female from colon cancer, 18 and 
11 months after LT, respectively The other 6 deaths were related to surgery or to the disease and 
some of them have previously been described. A brief description of these 6 cases follows. A 22-
year-old female (Arg47) died during surgery from severe haemodynamic instability after graft 
reperfusion. The transplant operation had been complicated by rupture of the spleen, requiring a 
splenectomy; pathological examination of the spleen confirmed the presence of diffuse amyloid 
deposits (33). A 57-year-old male (Thr34), who received 2 LTs because of primary graft 
nonfunction, died 8 days after the second LT from cardiac complications; at basal myocardial 
biopsy, he had moderate myocardial damage.  A 43-year-old female (Pro36) died 21 days after 
LT from massive subarachnoideal haemorrhage; histological examination of the brain showed 
amyloid deposition in the subarachnoid and subpial vessels (Errore. Il segnalibro non è 
definito.).  A 54-year-old male (Gln89) died 2 months after combined HT-LT from sepsis and 
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multiorgan failure; in the postoperative period, he underwent 2 surgical operations for 
intrapericardial and  abdominal bleeding (34).  Finally, two males (a Gln89 45-year-old who also 
underwent HT, and a Met30 57-year-old) died 19 and 36 months after transplantation 
respectively from malabsorption. At the time of surgery, their mBMIs were 537 and 524, 
respectively. 
Prognostic factors 
In order to evaluate the factors affecting survival after LT for TTR amyloidosis, the follow-up of 
the 2 patients who died from causes related neither to surgery nor to the disease were considered 
censored at the time of death. 
Analysis of survival by type of mutation showed that patients with non-Met30 variants seem to 
have a higher risk of death after LT as compared to those with the Met30. One- and 5-year 
survival rates were 55.6% and 37.0% for non-Met30 vs. 100% and 75.0% for Met30 patients 
respectively, with a mean survival of 2.8 years (95% CI 0.6-5.0) and 10.6 years (95% CI 6.3-
15.0), respectively (HR 6.60, 95% CI 0.76-57.2; P=0.087) (Figure 1). 
Among the 9 patients with non-Met30 variants, a tendency towards a better prognosis for patients 
who received combined HT was observed, although it was not statistically significant (HR 0.14, 
95% CI 0.01-1.41; P=0.095); the 1-year survival rate was 80.0% for patients who received 
combined HT vs. 25.0% for patients who underwent LT alone. 
Nutritional status was significantly correlated to patient survival after transplantation, with a 
significant reduction in the risk of death for each increase of 100 units in mBMI (HR 0.54, 95% 
CI 0.30-0.94) (P=0.031). Survival was significantly worse (HR 5.18, 95% CI 1.03-26.1; P=0.046) 
in the 3 patients with an mBMI <600: 66.7% and 0% at 1 and 5 years than  in the 14 patients with 
an mBMI ≥600: 78.6% at both 1 and 5 years . Mean survival was 1.5 years (95% CI 0.0-3.2)  in 
the former group vs. 10.4 years (95% CI 7.6-13.2) in the latter group(Figure 2). 
None of the other parameters showed a significant impact on survival after LT: duration of 
symptoms before LT (P=0.582), grade of peripheral nervous system involvement (P=0.074), 
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orthostatic hypotension (P=0.280), bladder dysfunction (P=0.546), age at transplantation 
(P=1.000), combined HT-LT (P=0.996) and end-diastolic thickness of the interventricular septum 
(P=0.830 in the 12 patients who did not receive HT). 
At multivariate analysis, both non-Met30 mutations (HR 17.3, 95% CI 1.03-291.7) and mBMI 
(HR 0.50, 95% CI 0.29-0.87) showed a significant and independent prognostic impact on patient 
survival after transplantation (P=0.048 and P=0.015, respectively). 
Course of the clinical manifestations of amyloidosis after transplant 
The course of the clinical manifestations of amyloidosis was analysed in the 12 patients with a 
post-transplant follow-up ≥6 months. The median follow-up time after transplantation in this 
cohort was 2.2 years (range 0.9-13.2 years). The comparison of the clinical manifestations of 
amyloidosis at the end of the follow-up vs. the clinical manifestations at the time of transplant did 
not show a significant improvement of symptoms (P=1.000 for sensory-motor neuropathy, 
P=0.241 for mBMI, P=1.000 for orthostatic hypotension, P=1.000 for bladder dysfunction; 
McNemar and Wilcoxon tests). 
Regarding heart involvement, at follow-up, none of the 4 patients who had received combined 
HT-LT (3 with Gln89 and 1 with Leu68 mutations) acquired evidence of amyloid deposition in 
the transplanted heart at the yearly echocardiographic and histological evaluation. None of the 
remaining 8 patients who had undergone LT alone (7 with Met30 mutation, 1 with Ala49 
mutation) developed symptoms consistent with cardiac amyloidosis at follow-up. An 
echocardiogram, available in 4 of these 8 patients (all Met30), did not show a significant increase 
(P=0.317; Wilcoxon test) in end-diastolic thickness of the interventricular septum (14.5±3.0 mm 
at pre-transplant and 15.3±2.9 mm at follow-up). 
Domino transplantation 
We started to use sequential LT in May 2003; since then, 5 patients (2 males, 3 females) have 
received the harvested graft from patients with TTR amyloidosis (2 from Met30, 1 from Gln89, 1 
from Ala49 and 1 from Leu68 carriers). The mean age of the recipients at surgery was 52.8±12.8 
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years (range 33-64 yrs). Three patients underwent domino LT due to hepatocellular carcinoma 
from alcoholic (n=1) or viral cirrhosis (n=2), 1 due to HCV cirrhosis without cancer and 1 (a 33-
year-old female) due to a cholangiocarcinoma. This last patient received domino LT after the loss 
of a previous living graft from her homozygote twin due to late hepatic artery thrombosis; she 
also had a chronic HCV infection. 
The youngest patient (the 33-year-old female) died 17 months after domino LT from recurrent, 
cholestatic hepatitis C, in the absence of recurrent cholangiocarcinoma (20 months after the first 
LT). The other 4 patients are alive and in good condition. The median follow-up after domino LT 
is 1.2 years (range 0.2-3.2). None of the recipients of domino LT developed clinical evidence of 
amyloidosis at follow-up. 
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DISCUSSION  
Today, LT is considered the only definitive treatment for TTR amyloidosis since over 95% of 
TTR is produced by the liver; the rationale for LT is to stop disease progression by abolishing the 
supply of mutated protein. The five-year patient survival rate after LT is reported to be 77% (18), 
which is comparable to the survival of LT performed for chronic liver disease. However, the 
majority of studies in the literature report data from endemic countries where the Met30 mutation 
is predominant while the real benefit of LT for patients with other variants is still less clear.  
In our experience, the overall 5-year survival rate after LT was 43.8%. This value, which is 
notably below the average reported in the literature, probably depends on the higher prevalence 
of non-Met30 variants in our cohort of patients. In fact only 47.1% of our patients carried the 
Met30 mutation, compared to 83% in the Familial Amyloidotic World Transplant Registry  (18). 
Our speculation is supported by multivariate analysis which revealed a significant and 
independent higher risk of death for non-Met30 carriers after having adjusted for the differences 
in mBMI. 
Besides the TTR variant, ,  mBMI was also significantly associated with post-LT survival at 
multivariate analysis,.  The risk of death decrease 50% for each 100 unit increase of the mBMI; 
these data are consistent with the literature (27, 28, 29) and suggest that patients should undergo 
LT early when their nutritional status is still good. 
In our population 5 non-Met30 patients underwent combined LT-HT because of severe cardiac 
involvement. The rationale for such a policy was supported by the observations of an incremental 
surgical risks of LT in cardiomyopathic patients (19, 22), a poor prognostic impact of established 
severe cardiomyopathy in patients who survive LT (19), and the possibility of cardiomyopathy 
progression after LT alone (20, 21, 22, 23). Moreover, in our experience, even in non-
transplanted patients, cardiac involvement is a major component of the phenotypic expression of 
non-Met30 TTR amyloidosis. In particular, the ominous prognosis of the Gln89 carriers appears 
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to be mainly due to cardiovascular events, irrespective of the degree of neurological impairment 
(6).   
In our experience, HT combined with LT did not show a negative impact on survival and, at 
follow-up, none of these patients had evidence of amyloid deposition in the transplanted heart, 
confirming that this strategy is safe and effective for patients with heart involvement.  
Another controversial issue is the true ability of LT to halt the progression of the disease. In our 
population,  the symptoms of the disease stabilized in all patients after LT, but none of them 
showed a significant improvement thus suggesting that LT should be performed before the 
patient’s functional status has been compromised. 
In conclusion our experience although limited  by the low number of patients, confirms an 
excellent patient survival in Met30 carriers and a significantly lower survival in other variants. 
Carriers of non-Met30 variants with amyloidotic cardiomyopathy should be carefully evaluated  
in order to decide the need for combined HT-LT suggesting that the treatment should be tailored to 
the variant. An mBMI below 600 has been confirmed to be one of the most important negative 
prognostic factor for patient survival, and should probably be considered an absolute 
contraindication to LT. The absence of clinical improvement after surgery confirims that, when 
indicated, LT should be performed early in the course of the disease to improve survival and to 
ensure an acceptable quality of life. 
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